Entera Bio Announces Closing of Private Placement – Extends Cash Runway into 2025
JERUSALEM, Dec. 26, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ:ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with certain existing and new investors. The Company issued and sold 7,916,879 units at a price of $0.835 per unit, each consisting of one ordinary share of Entera (or one pre-funded warrant in lieu thereof), and one five-year warrant. Gross proceeds to Entera, before offering expenses, were approximately $6.6 million, extending the Company’s cash runway into 2025.
Related news for (ENTX)
- Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
- 24/7 Market News Snapshot 28 July, 2025 – Entera Bio Ltd. Ordinary Shares (NASDAQ:ENTX)
- Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
- Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
- Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis – Highlighted as Oral Presentation at WCO-IOF ESCEO